Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

Abstract Abrocitinib, an oral, once-daily, Janus kinase (JAK) 1-selective inhibitor, is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis (AD). Abrocitinib has shown rapid and sustained efficacy in phase 3 trials and a consistent, manageable safety profil...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Melinda J. Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, Michael J. Cork, Lawrence F. Eichenfield, Eric L. Simpson, Athanasios Tsianakas, Urs Kerkmann, Claire Feeney, William Romero
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2024-07-01
Edice:	Dermatology and Therapy
Témata:	Abrocitinib Atopic dermatitis JAK1-selective inhibitor Monitoring Safety
On-line přístup:	https://doi.org/10.1007/s13555-024-01200-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!